A M Tsimberidou
Overview
Explore the profile of A M Tsimberidou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gouda M, Shunyakova J, Naing A, Dumbrava E, Hong D, Yuan Y, et al.
ESMO Open
. 2024 Jun;
9(6):103486.
PMID: 38914452
Background: Paclitaxel resistance limits durability of response in patients with initial clinical benefit. Overexpression of spleen tyrosine kinase (SYK) has been proposed as a possible resistance mechanism. This phase I...
2.
Dumbrava E, Call S, Huang H, Stuckett A, Madwani K, Adat A, et al.
ESMO Open
. 2021 Sep;
6(5):100230.
PMID: 34479035
Background: Oncogenic mutations in PIK3CA are prevalent in diverse cancers and can be targeted with inhibitors of the phosphoinositide-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Analysis of circulating tumor...
3.
Liu L, Toung J, Jassowicz A, Vijayaraghavan R, Kang H, Zhang R, et al.
Ann Oncol
. 2018 Apr;
29(6):1445-1453.
PMID: 29635542
Background: Targeted methylation sequencing of plasma cell-free DNA (cfDNA) has a potential to expand liquid biopsies to patients with tumors without detectable oncogenic alterations, which can be potentially useful in...
4.
Janku F, Huang H, Fujii T, Shelton D, Madwani K, Fu S, et al.
Ann Oncol
. 2016 Dec;
28(3):642-650.
PMID: 27993791
Background: Cell-free DNA (cfDNA) from plasma offers easily obtainable material for KRAS mutation analysis. Novel, multiplex, and accurate diagnostic systems using small amounts of DNA are needed to further the...
5.
Liu X, George G, Tsimberidou A, Naing A, Wheler J, Kopetz S, et al.
BMC Cancer
. 2015 Oct;
15:713.
PMID: 26474549
Background: This retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by evaluating the impact of prior activity...
6.
Said R, Banchs J, Wheler J, Hess K, Falchook G, Fu S, et al.
Ann Oncol
. 2013 Dec;
25(1):276-82.
PMID: 24356639
Background: New targeted agents may cause acute cardiac events. The purpose of our study was to investigate the incidence and the prognostic significance of left ventricular ejection fraction (LVEF) in...
7.
Veasey Rodrigues H, Baracos V, Wheler J, Parsons H, Hong D, Naing A, et al.
Eur J Cancer
. 2013 Jul;
49(15):3068-75.
PMID: 23867127
Purpose: Delineate the relationships between body composition parameters, 90-day mortality and overall survival, and correlate them with known prognostic factors in an early clinical trials clinic. Patients And Methods: We...
8.
Wheler J, Falchook G, Tsimberidou A, Hong D, Naing A, Piha-Paul S, et al.
Ann Oncol
. 2012 Nov;
24(3):838-42.
PMID: 23139256
Background: Epidermal growth factor receptor (EGFR) mutations are associated with the response to EGFR inhibitors in patients with non-small-cell lung cancer (NSCLC). We sought to investigate EGFR aberrations in patients...
9.
Naing A, Veasey-Rodrigues H, Hong D, Fu S, Falchook G, Wheler J, et al.
Ann Oncol
. 2012 Jun;
23(11):2960-2963.
PMID: 22745218
Background: Cardiac sequelae from oncologic drugs are important in early cancer drug development. Prolongation of the corrected QT interval (QTc) by noncardiac drugs is the most common cause of drug...
10.
Wheler J, Tsimberidou A, Hong D, Naing A, Falchook G, Fu S, et al.
Ann Oncol
. 2012 Mar;
23(8):1963-1967.
PMID: 22377564
Background: This study assessed toxicity in advanced cancer patients treated in a phase I clinic that focuses on targeted agents. Patients And Methods: An analysis of database records of 1181...